HealthMore in Health→
Incyte Moves Toward a Vitiligo Filing After Twin Phase 3 Successes
Key Takeaways
- Incyte says povorcitinib succeeded in twin Phase 3 vitiligo trials.
- The company plans to seek approval in nonsegmental vitiligo.
- The update moves the program from late-stage development into regulatory preparation.
DE
DT Editorial Team··via endpoints.news
